References
- Cervantes F. How I treat myelofibrosis. Blood 2014; 124:2635–2642.
- Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–2390.
- Lambertenghi-Deliliers G, Orazi A, Luksch R, et al. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol 1991; 78: 161–166.
- Bae E, Park CJ, Cho YU, et al. Differential diagnosis of myelofibrosis based on WHO 2008 criteria: acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis. Int J Lab Hematol 2013; 35: 629–636.
- Paquette RL, Meshkinpour A, Rosen PJ. Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. Medicine (Baltimore) 1994; 73: 145–152.
- Vergara-Lluri ME, Piatek CI, Pullarkat V, Siddiqi IN, et al. Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature. Hum Pathol 2014; 45: 2183–2191.
- Pullarkat V, Bass RD, Gong JZ, et al. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. Am J Hematol 2003; 72: 8–12.
- Aharon A, Levy Y, Bar-Dayan Y, et al. Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 1997; 6: 408–411.
- Harrison JS, Corcoran KE, Joshi D, et al. Peripheral monocytes and CD4+ cells are potential sources for increased circulating levels of TGF-beta and substance P in autoimmune myelofibrosis. Am J Hematol 2006; 81:51–58.
- Kiss E, Gal I, Simkovics E, et al. Myelofibrosis in systemic lupus erythematosus. Leuk Lymphoma 2000;39: 661–665.
- Feng CS, Ng MH, Szeto RS, et al. Bone marrow findings in lupus patients with pancytopenia. Pathology 1991; 23: 5–7.
- Dalal BI, Keown PA, Paraskevas F, et al. Cytokine profile in acute myelofibrosis associated with aggressive large granular lymphocyte leukemia. Am J Hematol 1995; 49: 349–352.
- Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012; 119: 3219–3225.
- Hasselbalch HC. A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis? Leuk Res 2014; 38: 263–266.
- Giannoutsos I, Heaton D. Autoimmune marrow fibrosis with cytopenias responsive to methotrexate. Leuk Lymphoma 2006; 47: 1674–1676.
- Centenara E, Guarnone R, Ippoliti G, et al. Cyclosporin-A in severe refractory anemia of myelofibrosis with myeloid metaplasia: a preliminary report. Haematologica 1998; 83: 622–626.
- Chalayer E, Ffrench M, Cathebras P. Bone marrow fibrosis as a feature of systemic lupus erythematosus: a case report and literature review. Springerplus 2014; 3: 349.
- Santos FP, Konoplev SN, Lu H, et al. Primary autoimmune myelofibrosis in a 36-year-old patient presenting with isolated extreme anemia. Leuk Res 2010; 34: e35–e37.
- Kelaidi C, Park S, Sapena R, et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia 2013; 27:1283–1290.